 "PM Modi")
Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant
Bharat Biotech has updated the efficacy of Covaxin to 65.2% against the Delta variant in - Effectiveness Study on Delta Variant - Lancet Infectious Diseases, published on Nov 23 2021.
"Bharat Biotech commends the investigators from the All India Institute of Medical Sciences (AIIMS) on the BBV152 study published in Lancet Infectious Diseases. These results provide evidence for effectiveness for Covaxin in real life settings," Bharat Biotech said. Read more
ITC starts clinical trials for nasal spray to prevent Covid-19 infection
Diversified conglomerate, ITC, is developing a nasal spray for Covid-19 prevention for
